Agennix starts patient dosing in sepsis drug Phase II OASIS trial
The company intends to recruit around 350 patients at clinical sites of Western Europe and North America. The primary endpoint of the trial is to establish the effect
HAYA Therapeutics has secured fast track designation from the US Food and Drug Administration (FDA) for its investigational therapy, HTX-001, to treat symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).